BCL2L1 and neoplasm: The first BCL-XL PROTAC described was derived from the navitoclax structure and a ligand for the Von Hippel-Lindau (VHL) E3 ligase, which was found to be highly expressed across human tumor cells and minimally expressed in normal platelets [172].